Insilico Medicine Receives FDA IND Approval for ISM8969
I'm PortAI, I can summarize articles.
Insilico Medicine Cayman Topco has received FDA IND approval for ISM8969, an AI-driven NLRP3 inhibitor, which is considered a potential best-in-class candidate. The drug has undergone extensive preclinical evaluation in various neurological disease models. No other organizations were mentioned in the announcement.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments